{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:36:19Z","timestamp":1778934979267,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["MOST-108-2320-B-006-014"],"award-info":[{"award-number":["MOST-108-2320-B-006-014"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["MOST-109-2320-B-006-023"],"award-info":[{"award-number":["MOST-109-2320-B-006-023"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["MOST-110-2320-B-006-051"],"award-info":[{"award-number":["MOST-110-2320-B-006-051"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Tumor vascular mimicry is an emerging issue that affects patient survival while having no treatment at the current moment. Despite several factors implicated in vascular mimicry, little is known about stromal factors that modulate tumor microenvironment and shape malignant transformation. CD248, a type-I transmembrane protein dominantly expressed in stromal cells, mediates the interaction between cells and extracellular matrix proteins. CD248 protein expression is associated with the metastatic melanoma phenotype and promotes tumor progression in the stromal cells. This study aimed to explore the cell-autonomous effects of CD248 in melanoma vascular mimicry to aid cancer therapy development.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Loss-of-function approaches in B16F10 melanoma cells were used to study the cell-autonomous effects of CD248 on cell adhesion, migration, proliferation, and vascular mimicry. A solid-phase binding assay was performed to identify the interaction between CD248 and fibronectin. Horizontal and vertical cell migration assays were performed to analyze cell migration activity, and cell-patterned network formation on Matrigel was used to evaluate vascular mimicry activity. Recombinant CD248 (rCD248) proteins were generated, and whether rCD248 interfered with melanoma CD248 functions was evaluated in vitro. An experimental lung metastasis mouse model was used to investigate the effect of rCD248 treatment in vivo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>CD248 protein expression in melanoma cells was increased by a fibroblast-conditioned medium. Knockdown of <jats:italic>CD248<\/jats:italic> expression significantly decreased cell adhesion to fibronectin, cell migration, and vascular mimicry in melanoma cells. The lectin domain of CD248 was directly involved in the interaction between CD248 and fibronectin. Furthermore, rCD248 proteins containing its lectin domain inhibited cell adhesion to fibronectin and slowed down cell migration and vascular mimicry. Treatment with rCD248 protein could reduce pulmonary tumor burden, accompanied by a reduction in vascular mimicry in mice with melanoma lung metastasis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>CD248 expression in melanoma cells promotes malignant transformation by increasing the activity of cell adhesion, migration, and vascular mimicry, whereas rCD248 protein functions as a molecular decoy interfering with tumor-promoting effects of CD248 in melanoma cells.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12929-022-00882-3","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T04:51:09Z","timestamp":1668747069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Interference in melanoma CD248 function reduces vascular mimicry and metastasis"],"prefix":"10.1186","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4885-9020","authenticated-orcid":false,"given":"Cheng-Hsiang","family":"Kuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Fang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bi-Ing","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Kai","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Han","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"issue":"9","key":"882_CR1","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.3390\/ijms17091489","volume":"17","author":"MP Pinto","year":"2016","unstructured":"Pinto MP, et al. Escaping antiangiogenic therapy: strategies employed by Cancer cells. Int J Mol Sci. 2016;17(9):1489.","journal-title":"Int J Mol Sci"},{"key":"882_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1318","author":"F Pezzella","year":"2020","unstructured":"Pezzella F, Ribatti D. Vascular co-option and vasculogenic mimicry mediate resistance to antiangiogenic strategies. Cancer Rep (Hoboken). 2020. https:\/\/doi.org\/10.1002\/cnr2.1318.","journal-title":"Cancer Rep (Hoboken)."},{"key":"882_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3389\/fonc.2019.00803","volume":"9","author":"M Fernandez-Cortes","year":"2019","unstructured":"Fernandez-Cortes M, Delgado-Bellido D, Oliver FJ. Vasculogenic mimicry: become an endothelial cell \u201cBut Not So Much.\u201d Front Oncol. 2019;9:803.","journal-title":"Front Oncol"},{"issue":"3","key":"882_CR4","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0002-9440(10)65173-5","volume":"155","author":"AJ Maniotis","year":"1999","unstructured":"Maniotis AJ, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155(3):739\u201352.","journal-title":"Am J Pathol"},{"issue":"6292","key":"882_CR5","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1126\/science.352.6292.1381","volume":"352","author":"M Leslie","year":"2016","unstructured":"Leslie M. Tumors\u2019 do-it-yourself blood vessels. Science. 2016;352(6292):1381\u20133.","journal-title":"Science"},{"issue":"3","key":"882_CR6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s12253-018-0496-3","volume":"25","author":"HY Ren","year":"2019","unstructured":"Ren HY, et al. Correlation between tumor vasculogenic mimicry and poor prognosis of human digestive cancer patients: a systematic review and meta-analysis. Pathol Oncol Res. 2019;25(3):849\u201358.","journal-title":"Pathol Oncol Res"},{"issue":"18","key":"882_CR7","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1016\/j.ejca.2013.07.148","volume":"49","author":"Z Cao","year":"2013","unstructured":"Cao Z, et al. Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer. 2013;49(18):3914\u201323.","journal-title":"Eur J Cancer"},{"key":"882_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2016.01.006","volume":"159","author":"MJ Hendrix","year":"2016","unstructured":"Hendrix MJ, et al. Tumor cell vascular mimicry: novel targeting opportunity in melanoma. Pharmacol Ther. 2016;159:83\u201392.","journal-title":"Pharmacol Ther"},{"issue":"9","key":"882_CR9","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1111\/jcmm.12851","volume":"20","author":"Q Liu","year":"2016","unstructured":"Liu Q, et al. The relationship between vasculogenic mimicry and epithelial-mesenchymal transitions. J Cell Mol Med. 2016;20(9):1761\u20139.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"882_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.20892\/j.issn.2095-3941.2018.0209","volume":"16","author":"H Sun","year":"2019","unstructured":"Sun H, et al. Cancer stem-like cells directly participate in vasculogenic mimicry channels in triple-negative breast cancer. Cancer Biol Med. 2019;16(2):299\u2013311.","journal-title":"Cancer Biol Med"},{"key":"882_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.biopha.2016.03.010","volume":"80","author":"S Li","year":"2016","unstructured":"Li S, et al. The hypoxia-related signaling pathways of vasculogenic mimicry in tumor treatment. Biomed Pharmacother. 2016;80:127\u201335.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"882_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12943-017-0631-x","volume":"16","author":"D Delgado-Bellido","year":"2017","unstructured":"Delgado-Bellido D, et al. Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin. Mol Cancer. 2017;16(1):65.","journal-title":"Mol Cancer"},{"key":"882_CR13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3389\/fonc.2019.01419","volume":"9","author":"ON de la Hern\u00e1ndezCruz","year":"2019","unstructured":"Hern\u00e1ndez de la Cruz, ON, et al. Regulation networks driving vasculogenic mimicry in solid tumors. Front Oncol. 2019;9:1419.","journal-title":"Front Oncol"},{"key":"882_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-3-319-78127-3_6","volume":"1060","author":"AE Denton","year":"2018","unstructured":"Denton AE, Roberts EW, Fearon DT. Stromal cells in the tumor microenvironment. Adv Exp Med Biol. 2018;1060:99\u2013114.","journal-title":"Adv Exp Med Biol"},{"key":"882_CR15","doi-asserted-by":"publisher","first-page":"696931","DOI":"10.3389\/fonc.2021.696931","volume":"11","author":"YM Tsai","year":"2021","unstructured":"Tsai YM, et al. Cooperation between cancer and fibroblasts in vascular mimicry and N2-Type neutrophil recruitment via Notch2-Jagged1 interaction in lung cancer. Front Oncol. 2021;11:696931.","journal-title":"Front Oncol"},{"issue":"46","key":"882_CR16","doi-asserted-by":"publisher","first-page":"17965","DOI":"10.1073\/pnas.0705647104","volume":"104","author":"B Tomkowicz","year":"2007","unstructured":"Tomkowicz B, et al. Interaction of endosialin\/TEM1 with extracellular matrix proteins mediates cell adhesion and migration. Proc Natl Acad Sci U S A. 2007;104(46):17965\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"882_CR17","doi-asserted-by":"publisher","first-page":"993","DOI":"10.18632\/oncotarget.26590","volume":"10","author":"BA Teicher","year":"2019","unstructured":"Teicher BA. CD248: a therapeutic target in cancer and fibrotic diseases. Oncotarget. 2019;10(9):993\u20131009.","journal-title":"Oncotarget"},{"issue":"5\u20136","key":"882_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.gep.2011.03.001","volume":"11","author":"HP Huang","year":"2011","unstructured":"Huang HP, et al. Gene targeting and expression analysis of mouse Tem1\/endosialin using a lacZ reporter. Gene Expr Patterns. 2011;11(5\u20136):316\u201326.","journal-title":"Gene Expr Patterns"},{"issue":"9","key":"882_CR19","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1073\/pnas.0511306103","volume":"103","author":"A Nanda","year":"2006","unstructured":"Nanda A, et al. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc Natl Acad Sci U S A. 2006;103(9):3351\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"882_CR20","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1158\/0008-5472.CAN-16-0932","volume":"76","author":"C Viski","year":"2016","unstructured":"Viski C, et al. Endosialin-expressing pericytes promote metastatic dissemination. Cancer Res. 2016;76(18):5313\u201325.","journal-title":"Cancer Res"},{"issue":"2","key":"882_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3892\/ol.2021.13160","volume":"23","author":"Y Kondo","year":"2022","unstructured":"Kondo Y, et al. Endosialin\/CD248 may be a potential therapeutic target to prevent the invasion and metastasis in osteosarcoma. Oncol Lett. 2022;23(2):42.","journal-title":"Oncol Lett"},{"key":"882_CR22","doi-asserted-by":"publisher","first-page":"644612","DOI":"10.3389\/fonc.2021.644612","volume":"11","author":"K Zhang","year":"2021","unstructured":"Zhang K, et al. The diagnostic and immunotherapeutic value of CD248 in renal cell carcinoma. Front Oncol. 2021;11:644612.","journal-title":"Front Oncol"},{"issue":"2","key":"882_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12307-015-0168-8","volume":"8","author":"E Kiyohara","year":"2015","unstructured":"Kiyohara E, et al. Endosialin expression in metastatic melanoma tumor microenvironment vasculature: potential therapeutic implications. Cancer Microenviron. 2015;8(2):111\u20138.","journal-title":"Cancer Microenviron"},{"issue":"5","key":"882_CR24","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/ATVBAHA.121.315931","volume":"41","author":"CH Kuo","year":"2021","unstructured":"Kuo CH, et al. VEGF-Induced endothelial podosomes via ROCK2-dependent thrombomodulin expression initiate sprouting angiogenesis. Arterioscler Thromb Vasc Biol. 2021;41(5):1657\u201371.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"882_CR25","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.jid.2019.03.1149","volume":"139","author":"YK Hong","year":"2019","unstructured":"Hong YK, et al. Tumor endothelial marker 1 (TEM1\/Endosialin\/CD248) enhances Wound Healing by interacting with platelet-derived growth factor receptors. J Invest Dermatol. 2019;139(10):2204\u201314.e7.","journal-title":"J Invest Dermatol"},{"issue":"42","key":"882_CR26","doi-asserted-by":"publisher","first-page":"68122","DOI":"10.18632\/oncotarget.11828","volume":"7","author":"YY Hsu","year":"2016","unstructured":"Hsu YY, et al. Thrombomodulin promotes focal adhesion kinase activation and contributes to angiogenesis by binding to fibronectin. Oncotarget. 2016;7(42):68122\u201339.","journal-title":"Oncotarget"},{"issue":"9","key":"882_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1089\/hum.2013.220","volume":"26","author":"CH Kuo","year":"2015","unstructured":"Kuo CH, et al. Development of recombinant adeno-associated virus serotype 2\/8 carrying Kringle domains of human plasminogen for sustained expression and cancer therapy. Hum Gene Ther. 2015;26(9):603\u201313.","journal-title":"Hum Gene Ther"},{"key":"882_CR28","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.2147\/OTT.S195703","volume":"12","author":"B Li","year":"2019","unstructured":"Li B, et al. Fibronectin 1 promotes melanoma proliferation and metastasis by inhibiting apoptosis and regulating EMT. Onco Targets Ther. 2019;12:3207\u201321.","journal-title":"Onco Targets Ther"},{"key":"882_CR29","doi-asserted-by":"publisher","first-page":"5200","DOI":"10.1038\/ncomms6200","volume":"5","author":"JM Dunleavey","year":"2014","unstructured":"Dunleavey JM, et al. Vascular channels formed by subpopulations of PECAM1 + melanoma cells. Nat Commun. 2014;5:5200.","journal-title":"Nat Commun"},{"issue":"20","key":"882_CR30","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1158\/0008-5472.CAN-22-1695","volume":"82","author":"CL Hong","year":"2022","unstructured":"Hong CL, et al. CD248 regulates wnt signaling in pericytes to promote angiogenesis and tumor growth in lung cancer. Cancer Res. 2022;82(20):3737\u201350.","journal-title":"Cancer Res"},{"issue":"12","key":"882_CR31","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/jnen\/63.12.1274","volume":"63","author":"J Brady","year":"2004","unstructured":"Brady J, et al. Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors. J Neuropathol Exp Neurol. 2004;63(12):1274\u201383.","journal-title":"J Neuropathol Exp Neurol"},{"key":"882_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/1471-2407-11-162","volume":"11","author":"M Maia","year":"2011","unstructured":"Maia M, et al. CD248 facilitates tumor growth via its cytoplasmic domain. BMC Cancer. 2011;11:162.","journal-title":"BMC Cancer"},{"issue":"11","key":"882_CR33","doi-asserted-by":"publisher","first-page":"908","DOI":"10.4161\/cbt.9.11.11731","volume":"9","author":"B Tomkowicz","year":"2010","unstructured":"Tomkowicz B, et al. Endosialin\/TEM-1\/CD248 regulates pericyte proliferation through PDGF receptor signaling. Cancer Biol Ther. 2010;9(11):908\u201315.","journal-title":"Cancer Biol Ther"},{"issue":"7","key":"882_CR34","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1182\/blood-2011-01-332338","volume":"120","author":"N Simonavicius","year":"2012","unstructured":"Simonavicius N, et al. Pericytes promote selective vessel regression to regulate vascular patterning. Blood. 2012;120(7):1516\u201327.","journal-title":"Blood"},{"issue":"3","key":"882_CR35","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1365-2567.2011.03437.x","volume":"133","author":"DL Hardie","year":"2011","unstructured":"Hardie DL, et al. The stromal cell antigen CD248 (endosialin) is expressed on naive CD8 + human T cells and regulates proliferation. Immunology. 2011;133(3):288\u201395.","journal-title":"Immunology"},{"key":"882_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.trsl.2021.03.009","volume":"232","author":"TL Cheng","year":"2021","unstructured":"Cheng TL, et al. Role of tumor endothelial marker 1 (Endosialin\/CD248) lectin-like domain in lipopolysaccharide-induced macrophage activation and sepsis in mice. Transl Res. 2021;232:150\u201362.","journal-title":"Transl Res"},{"issue":"12","key":"882_CR37","doi-asserted-by":"publisher","first-page":"6328","DOI":"10.4049\/jimmunol.1102266","volume":"188","author":"CY Ma","year":"2012","unstructured":"Ma CY, et al. Monocytic thrombomodulin triggers LPS- and gram-negative bacteria-induced inflammatory response. J Immunol. 2012;188(12):6328\u201337.","journal-title":"J Immunol"},{"issue":"7","key":"882_CR38","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1136\/gutjnl-2014-308325","volume":"65","author":"A Wilhelm","year":"2016","unstructured":"Wilhelm A, et al. CD248\/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism. Gut. 2016;65(7):1175\u201385.","journal-title":"Gut"},{"issue":"9","key":"882_CR39","doi-asserted-by":"publisher","first-page":"e107146","DOI":"10.1371\/journal.pone.0107146","volume":"9","author":"AJ Naylor","year":"2014","unstructured":"Naylor AJ, et al. A differential role for CD248 (endosialin) in PDGF-mediated skeletal muscle angiogenesis. PLoS One. 2014;9(9):e107146.","journal-title":"PLoS One"},{"key":"882_CR40","doi-asserted-by":"publisher","first-page":"771036","DOI":"10.3389\/fonc.2021.771036","volume":"11","author":"Y Li","year":"2021","unstructured":"Li Y, et al. Prognostic value of vascular-expressed PSMA and CD248 in Urothelial Carcinoma of the bladder. Front Oncol. 2021;11:771036.","journal-title":"Front Oncol"},{"issue":"3","key":"882_CR41","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/modpathol.3801006","volume":"21","author":"N Simonavicius","year":"2008","unstructured":"Simonavicius N, et al. Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. Mod Pathol. 2008;21(3):308\u201315.","journal-title":"Mod Pathol"},{"key":"882_CR42","doi-asserted-by":"publisher","first-page":"773063","DOI":"10.3389\/fonc.2021.773063","volume":"11","author":"C Xu","year":"2021","unstructured":"Xu C, et al. CD248(+) cancer-associated fibroblasts: a novel prognostic and therapeutic target for renal cell carcinoma. Front Oncol. 2021;11:773063.","journal-title":"Front Oncol"},{"issue":"4","key":"882_CR43","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/bjc.2016.214","volume":"115","author":"K Thway","year":"2016","unstructured":"Thway K, et al. Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells. Br J Cancer. 2016;115(4):473\u20139.","journal-title":"Br J Cancer"},{"issue":"18","key":"882_CR44","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1158\/0008-5472.CAN-19-2691","volume":"80","author":"F Yang","year":"2020","unstructured":"Yang F, et al. Interaction with CD68 and regulation of GAS6 expression by endosialin in fibroblasts drives recruitment and polarization of Macrophages in Hepatocellular Carcinoma. Cancer Res. 2020;80(18):3892\u2013905.","journal-title":"Cancer Res"},{"issue":"1","key":"882_CR45","doi-asserted-by":"publisher","first-page":"16772","DOI":"10.1038\/s41598-020-73194-x","volume":"10","author":"CH Pai","year":"2020","unstructured":"Pai CH, et al. Targeting fibroblast CD248 attenuates CCL17-expressing macrophages and tissue fibrosis. Sci Rep. 2020;10(1):16772.","journal-title":"Sci Rep"},{"issue":"2","key":"882_CR46","doi-asserted-by":"publisher","first-page":"e22102","DOI":"10.1096\/fj.202101441R","volume":"36","author":"C Xu","year":"2022","unstructured":"Xu C, et al. Antibody-drug conjugates targeting CD248(+) myofibroblasts effectively alleviate renal fibrosis in mice. FASEB J. 2022;36(2):e22102.","journal-title":"FASEB J"},{"issue":"28","key":"882_CR47","doi-asserted-by":"publisher","first-page":"25429","DOI":"10.18632\/oncotarget.4559","volume":"6","author":"K Rybinski","year":"2015","unstructured":"Rybinski K, et al. Targeting endosialin\/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. Oncotarget. 2015;6(28):25429\u201340.","journal-title":"Oncotarget"},{"issue":"1","key":"882_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10637-017-0530-4","volume":"36","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, et al. A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma. Invest New Drugs. 2018;36(1):103\u201313.","journal-title":"Invest New Drugs"},{"issue":"14","key":"882_CR49","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/cncr.32084","volume":"125","author":"RL Jones","year":"2019","unstructured":"Jones RL, et al. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. Cancer. 2019;125(14):2445\u201354.","journal-title":"Cancer"},{"issue":"8","key":"882_CR50","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1096\/fj.07-101386","volume":"22","author":"R Becker","year":"2008","unstructured":"Becker R, et al. Tumor stroma marker endosialin (Tem1) is a binding partner of metastasis-related protein Mac-2 BP\/90\u2009K. FASEB J. 2008;22(8):3059\u201367.","journal-title":"FASEB J"},{"issue":"44","key":"882_CR51","doi-asserted-by":"publisher","first-page":"6097","DOI":"10.1038\/onc.2017.214","volume":"36","author":"KA Khan","year":"2017","unstructured":"Khan KA, et al. Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface. Oncogene. 2017;36(44):6097\u2013108.","journal-title":"Oncogene"},{"issue":"6","key":"882_CR52","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.copbio.2008.10.001","volume":"19","author":"JM Gershoni","year":"2008","unstructured":"Gershoni JM. Molecular decoys: antidotes, therapeutics and immunomodulators. Curr Opin Biotechnol. 2008;19(6):644\u201351.","journal-title":"Curr Opin Biotechnol"}],"updated-by":[{"DOI":"10.1186\/s12929-025-01155-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000}}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-022-00882-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-022-00882-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-022-00882-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T21:11:44Z","timestamp":1757106704000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-022-00882-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["882"],"URL":"https:\/\/doi.org\/10.1186\/s12929-022-00882-3","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12929-025-01155-5","asserted-by":"object"}]},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"assertion":[{"value":"8 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12929-025-01155-5","URL":"https:\/\/doi.org\/10.1186\/s12929-025-01155-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal study was conducted following the experimental protocol (110085) approved by the Institutional Animal Care and Use Committee of National Cheng Kung University and all procedures conformed to the NIH Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}